Swiss National Bank
ACRS icon

Swiss National Bank’s Aclaris Therapeutics ACRS Stock Holding History

Swiss National Bank’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-108,900
Closed -$114K – 2506
2023
Q4 		$114K Hold
108,900
– – ﹤0.01% 2533
2023
Q3 		$746K Hold
108,900
– – ﹤0.01% 2391
2023
Q2 		$1.13M Buy
108,900
+8,100
+8% +$73.3K ﹤0.01% 2225
2023
Q1 		$815K Sell
100,800
-11,800
-10% -$150K ﹤0.01% 2364
2022
Q4 		$1.77M Buy
112,600
+2,100
+2% +$33.8K ﹤0.01% 1963
2022
Q3 		$1.74M Buy
110,500
+9,500
+9% +$150K ﹤0.01% 1966
2022
Q2 		$1.41M Sell
101,000
-7,500
-7% -$105K ﹤0.01% 2157
2022
Q1 		$1.87M Buy
108,500
+7,500
+7% +$102K ﹤0.01% 2074
2021
Q4 		$1.47M Buy
101,000
+3,800
+4% +$57.6K ﹤0.01% 2243
2021
Q3 		$1.75M Hold
97,200
– – ﹤0.01% 2139
2021
Q2 		$1.71M Buy
+97,200
New +$2.21M ﹤0.01% 2211
2019
Q2 		– Sell
-63,400
Closed -$380K – 2555
2019
Q1 		$380K Buy
63,400
+5,400
+9% +$35.8K ﹤0.01% 2427
2018
Q4 		$429K Buy
58,000
+16,100
+38% +$166K ﹤0.01% 2403
2018
Q3 		$608K Hold
41,900
– – ﹤0.01% 2361
2018
Q2 		$837K Hold
41,900
– – ﹤0.01% 2267
2018
Q1 		$734K Buy
41,900
+2,600
+7% +$55.1K ﹤0.01% 2256
2017
Q4 		$969K Hold
39,300
– – ﹤0.01% 2112
2017
Q3 		$1.01M Buy
39,300
+10,000
+34% +$268K ﹤0.01% 2059
2017
Q2 		$795K Hold
29,300
– – ﹤0.01% 2189
2017
Q1 		$874K Hold
29,300
– – ﹤0.01% 2111
2016
Q4 		$795K Buy
29,300
+14,000
+92% +$357K ﹤0.01% 2176
2016
Q3 		$392K Hold
15,300
– – ﹤0.01% 2423
2016
Q2 		$283K Buy
+15,300
New +$303K ﹤0.01% 2523

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Swiss National Bank's ACRS Position: Q1 2024 in Review

Swiss National Bank sold out of Aclaris Therapeutics (ACRS) in Q1 2024, closing a stake of 108,900 shares — an estimated $114K sold.

Swiss National Bank first reported a position in ACRS in Q2 2016 and held it in 23 quarters. The position peaked at $1.87M in Q1 2022. 98 funds tracked by Wall St. Rank hold ACRS as of Q1 2024.

  • Swiss National Bank reported no remaining Aclaris Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Swiss National Bank sold 108,900 Aclaris Therapeutics shares in Q1 2024, an estimated $114K.
  • Swiss National Bank first reported a position in Aclaris Therapeutics in Q2 2016 and held it in 23 quarters.
  • Swiss National Bank's Aclaris Therapeutics position peaked at $1.87M in Q1 2022.
  • 98 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2024.

Based on Swiss National Bank's 13F filing for Q1 2024, filed 7 May 2024.